Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a novel class of oral hypoglycemic agents (OHAs) that have been authorized for use in the treatment of T2DM [9]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.